Amgen – Zenith Cure

Amgen’s Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects – Amgen (NASDAQ:AMGN)

Amgen Inc AMGN on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab…